Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2325 of 3499 entries
View as:

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00121199 Org: User:
Start: 06/30/05 End: 12/31/10 Due: 12/31/11

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019201 Org: User:
Start: 08/31/96 End: - Due: -

Depsipeptide in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00019318 Org: User:
Start: 08/31/97 End: - Due: -

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00041041 Org: User:
Start: 06/30/02 End: - Due: -

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00049114 Org: User:
Start: 02/28/03 End: - Due: -

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Phase: N/A Priority: Normal
NCT ID: NCT00026169 Org: User:
Start: 09/30/01 End: - Due: -

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04034238 Org: User:
Start: 08/29/19 End: 11/19/21 Due: 11/19/22

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019552 Org: User:
Start: 09/30/98 End: 04/30/04 Due: 04/30/05

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01447914 Org: User:
Start: 11/30/11 End: 04/30/14 Due: 04/30/15

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00051311 Org: User:
Start: 01/03/03 End: 09/25/14 Due: 09/25/15

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01168219 Org: User:
Start: 07/15/10 End: 02/01/20 Due: 02/01/21

Genetic Epidemiology of Lung Cancer and Smoking

Phase: N/A Priority: Normal
NCT ID: NCT00340340 Org: User:
Start: 06/28/01 End: 06/26/20 Due: 06/26/21

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03905135 Org: User:
Start: 06/07/19 End: 05/17/22 Due: 05/17/23

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00055913 Org: User:
Start: 03/31/03 End: - Due: -

Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients

Phase: N/A Priority: Normal
NCT ID: NCT01424878 Org: User:
Start: 07/05/10 End: 02/12/14 Due: 02/12/15

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01567709 Org: User:
Start: 04/16/12 End: 03/29/18 Due: 03/29/19

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002589 Org: User:
Start: 07/31/94 End: - Due: -

Safety of Batracylin in Patients With Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00450502 Org: User:
Start: 02/24/07 End: 04/24/11 Due: 04/24/12

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01688973 Org: User:
Start: 08/20/12 End: 04/30/17 Due: 04/30/18

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Phase: N/A Priority: Normal
NCT ID: NCT01434303 Org: User:
Start: 01/10/12 End: 02/16/16 Due: 02/16/17

Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews

Phase: N/A Priority: Normal
NCT ID: NCT00341900 Org: User:
Start: 11/09/01 End: 04/03/20 Due: 04/03/21

AZD7451 for Recurrent Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01468324 Org: User:
Start: 10/05/11 End: 04/23/14 Due: 04/23/15

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01349959 Org: User:
Start: 08/15/11 End: 11/07/23 Due: 11/07/24

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03255018 Org: User:
Start: 02/15/18 End: 06/29/23 Due: 06/29/24

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00884741 Org: User:
Start: 04/15/09 End: 03/17/13 Due: 03/17/14